Jiri Aubrecht, PharmD, PhDProfile
Jiri Aubrecht has been interested in the development of new approaches for genetic safety risk assessment applicable in drug development and environmental toxicology for many years. For instance, a novel high-throughput luminescent mutagenicity assay platform that was developed in his laboratory significantly decreased attrition of lead molecules and drug candidates due to genetic toxicity in drug development. Furthermore, in collaboration with the international HESI consortium, Dr. Aubrecht co-developed TGx-DDI genomic biomarker for genotoxicity which is currently under formal qualification review by the US FDA. His substantial contributions facilitated the success of the Superfund project by providing scientific and regulatory expertise in the development of new genetic safety testing approaches.